Reply Why to Replace an ACE or ARB With  an ARB/Neprilysin Inhibitor?

The American College of Cardiology (ACC) and American Heart Association (AHA) welcome letters to inform its ongoing work and encourage such correspondence about its clinical policy statements. Because the ACC/AHA guideline development process is rigorous and involves several layers of review by the writing committee, external peer reviewers, and participating organizations endorsing the document, there is limited editorial control over the content after publication. The information, however, gleaned from questions such as this is forwarded to the writing committee chairs and oversight Task Force for review. If any issues are deemed by the ACC or AHA to affect patient safety, they will be considered and addressed immediately. Otherwise, the information will be reviewed during the next revision of the document.

Source: Journal of the American College of Cardiology - November 22, 2016 Category: Cardiology Source Type: research